276 related articles for article (PubMed ID: 28063918)
1. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
[TBL] [Abstract][Full Text] [Related]
2. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples.
Chernet E; Martin LJ; Li D; Need AB; Barth VN; Rash KS; Phebus LA
Life Sci; 2005 Dec; 78(4):340-6. PubMed ID: 16139310
[TBL] [Abstract][Full Text] [Related]
3. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
Zhang W; Bymaster FP
Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
[TBL] [Abstract][Full Text] [Related]
4. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
Li HQ; Xu JY; Gao YY; Jin L
Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
[TBL] [Abstract][Full Text] [Related]
5. A positron emission tomography occupancy study of brexpiprazole at dopamine D
Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
Li Z; Huang J; Sun H; Zhou S; Guo L; Zhou Y; Zhen X; Liu H
Bioorg Med Chem; 2014 Nov; 22(21):5838-46. PubMed ID: 25308766
[TBL] [Abstract][Full Text] [Related]
7. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT
De Gregorio D; Posa L; Ochoa-Sanchez R; McLaughlin R; Maione S; Comai S; Gobbi G
Pharmacol Res; 2016 Nov; 113(Pt A):81-91. PubMed ID: 27544651
[TBL] [Abstract][Full Text] [Related]
8. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
[TBL] [Abstract][Full Text] [Related]
9. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.
Wong YC; Ilkova T; van Wijk RC; Hartman R; de Lange ECM
Eur J Pharm Sci; 2018 Jan; 111():514-525. PubMed ID: 29106979
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain.
Kusumi I; Takahashi Y; Suzuki K; Kameda K; Koyama T
J Neural Transm (Vienna); 2000; 107(3):295-302. PubMed ID: 10821438
[TBL] [Abstract][Full Text] [Related]
11. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
[TBL] [Abstract][Full Text] [Related]
12. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
13. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer.
Barth VN; Chernet E; Martin LJ; Need AB; Rash KS; Morin M; Phebus LA
Life Sci; 2006 May; 78(26):3007-12. PubMed ID: 16434058
[TBL] [Abstract][Full Text] [Related]
14. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
[TBL] [Abstract][Full Text] [Related]
16. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
[TBL] [Abstract][Full Text] [Related]
17. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
18. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.
Nakazawa S; Yokoyama C; Nishimura N; Horisawa T; Kawasaki A; Mizuma H; Doi H; Onoe H
Psychopharmacology (Berl); 2013 Jan; 225(2):329-39. PubMed ID: 22868411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
